

## Cinryze

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do\_not\_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Physician's Name: Specialty:		Date: Patient's Date of Birth:  NPI#: Physician Office Fax:	
	What is the diagnosis?  ☐ Hereditary angioedema (HAE) with C1 inhibitor defice ☐ HAE with normal C1 inhibitor confirmed by laborator ☐ Other	ry testing	
2.	What is the ICD-10 code?		
3.	Is Cinryze being used for the prevention of HAE attacks	? □ Yes □ No	
4.	How many HAE attacks does the patient have per month?		
5.	Will Cinryze be used in combination with Haegarda or T	akhzyro? □ Yes □ No	
5.	Has the patient previously received treatment with the re $\square$ Yes $\square$ No If No, skip to diagnosis section.	quested medication?	
7.	Has the patient experienced a significant reduction in fre starting treatment? <i>ACTION REQUIRED: If 'Yes'</i> , attafrequency of attacks. □ Yes □ No	quency of attacks (e.g. greater than or equal to 50%) since ach chart notes demonstrating a reduction in the	
8.	Has the patient reduced the use of medications to treat ac medication? ☐ Yes ☐ No	cute attacks since starting treatment with the requested	
Coi	mplete the following section based on the patient's diagn	osis, if applicable.	
		n Confirmed by Laboratory Testing f normal as defined by the laboratory performing the test? or medical record documentation confirming low C4 level.	
10.	Question continues on following page.	? ACTION REQUIRED: For any answer, attach ming C1 inhibitor functional and antigenic protein levels. wer limit of normal as defined by the laboratory performing	

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization. Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Cinryze SGM - 1/2021.

<ul> <li>angioedema.</li> <li>☐ F12, angiopoietin-1, plasminogen, or kininogen-1 (KNG1)</li> <li>☐ Family history of angioedema and angioedema refractory</li> </ul>	
at least one month  Other	
I attest that this information is accurate and true, and that information is available for review if requested by CVS Ca	

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization. Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Circyze SGM - 1/2021.